American Century Companies’s Entrada Therapeutics TRDA Stock Holding History

American Century Companies's TRDA Position: Q1 2026 in Review

American Century Companies increased its Entrada Therapeutics (TRDA) stake by 3.6% in Q1 2026, buying an estimated $30.8K and bringing the position to 77,971 shares worth $984K. The position accounts for ﹤0.01% of the portfolio, ranked #2332.

American Century Companies first reported a position in TRDA in Q2 2023 and has held it in 12 quarters since. The position peaked at $5.49M in Q2 2024. 120 funds tracked by Wall St. Rank hold TRDA as of Q1 2026.

• American Century Companies held 77,971 shares of Entrada Therapeutics worth $984K as of Q1 2026.
• American Century Companies bought 2,689 Entrada Therapeutics shares in Q1 2026, an estimated $30.8K.
• Entrada Therapeutics made up ﹤0.01% of American Century Companies's portfolio in Q1 2026, its #2332 holding.
• American Century Companies first reported a position in Entrada Therapeutics in Q2 2023 and has held it in 12 quarters since.
• American Century Companies's Entrada Therapeutics position peaked at $5.49M in Q2 2024.
• 120 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q1 2026.

Based on American Century Companies's 13F filing for Q1 2026, filed 15 May 2026.